N-Tosyl-5-bromo-4,7-diazaindole
- CAS NO.:1201186-54-0
- Empirical Formula: C13H10BrN3O2S
- Molecular Weight: 352.21
- MDL number: MFCD12964053
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-04-07 18:44:46
What is N-Tosyl-5-bromo-4,7-diazaindole?
The Uses of N-Tosyl-5-bromo-4,7-diazaindole
N-Tosyl-5-bromo-4,7-diazaindole is an intermediate of upadacitinib, known asupadacitinib intermediate, or upadacitinib impurity 2. As an inhibitor of Janus kinase1, upadacitinib selectively inhibits Janus kinase1 for immune system diseases such as psoriatic arthritis, rheumatoid arthritis, and Crohn's disease[1-3].
Preparation
A solution of anhydrous DMF (272 mL) dissolved with 2-bromo-5H-pyrrolo[2,3-b]pyrazine (78.0 g, 394 mmol) was configured. The temperature is maintained at 0-5 °C (within which the subsequent reaction has been maintained), and the solution was droppedly added to the sodium (12.8 g, 532 mmol) anhydrous DMF (543 mL) suspension in the stirred state within 60 minutes. The solution turned brown and the reaction solution was stirred for about 30 min. Then, within 60 minutes, anhydrous DMF (272 mL) dissolved with p-toluenesulfonyl chloride (94.0 g, 492 mmol) was added. After stirring the mixed solution for about 1 h, it was heated to ambient temperature and stirred for about 18 h. Slowly pour the reaction mixture into ice water (6 L) and added 2.5 N NaOH in water (50.0 mL, 125 mmol). Filter the sediment to collect and stirred 3 times with cold water (200 mL). Finally, the collected products were filtered and dried to a constant weight in a vacuum oven at about 55 °C to obtain N-Tosyl-5-bromo-4,7-diazaindole (134.6 g, 97%).
Safety
N-Tosyl-5-bromo-4,7-diazaindole can cause skin irritation, severe eye irritation, and possibly respiratory irritation.
References
[1] Yael Ross, Marina Magrey, Use of upadacitinib in the treatment of psoriatic arthritis, Immunotherapy, 2021, 13.
[2] Lina Serhal, Christopher J Edwards, Upadacitinib for the treatment of rheumatoid arthritis, Expert Review of Clinical Immunology, 2018, 15,13-25.
[3] Eleni Kotsiliti, Upadacitinib therapy for Crohn’s disease, Nature Reviews Gastroenterology & Hepatology, 2023, 20, 483.
Properties of N-Tosyl-5-bromo-4,7-diazaindole
Boiling point: | 499.6±55.0 °C(Predicted) |
Density | 1.68±0.1 g/cm3(Predicted) |
storage temp. | under inert gas (nitrogen or Argon) at 2-8°C |
pka | -2.22±0.30(Predicted) |
Safety information for N-Tosyl-5-bromo-4,7-diazaindole
Signal word | Warning |
Pictogram(s) |
Exclamation Mark Irritant GHS07 |
GHS Hazard Statements |
H302:Acute toxicity,oral H315:Skin corrosion/irritation H319:Serious eye damage/eye irritation H335:Specific target organ toxicity, single exposure;Respiratory tract irritation |
Precautionary Statement Codes |
P261:Avoid breathing dust/fume/gas/mist/vapours/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing. |
Computed Descriptors for N-Tosyl-5-bromo-4,7-diazaindole
Abamectin manufacturer
VGS SYNTHESIS PRIVATE LIMITED
Stereokem Pvt Ltd
New Products
COBALT AAS SOLUTION HYDROXYLAMINE HYDROCHLORIDE SOLUTION 10% THOMALIT BLUE LITMUS PAPER 1 BOX SILVER NITRATE N/10 CVS GLASS BEADS 3.5 TO 4.5 MM POTASSIUM AAS SOLUTION Azithromycin Imp D Atracurium Besylate EP Impurity C Ceftaroline fosamil Acetate Hydrate Clarithromycin EP impurity F Clarithromycin EP Impurity D Clindamycin BRelated products of tetrahydrofuran
You may like
-
1201186-54-0 3-Bromo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine 98%View Details
1201186-54-0 -
2-bromo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine 98%View Details
-
Atracurium Besylate EP Impurity CView Details
86293-35-8 -
Azithromycin Imp DView Details
612069-26-8 -
Ceftaroline fosamil Acetate HydrateView Details
400827-55-6 -
Clarithromycin EP Impurity FView Details
128940-83-0 -
Clarithromycin EP Impurity DView Details
101666-68-6 -
Clindamycin Impurity BView Details
18323-43-8